Skip to main
ORGO
ORGO logo

Organogenesis Holdings (ORGO) Stock Forecast & Price Target

Organogenesis Holdings (ORGO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Organogenesis Holdings Inc., a leader in regenerative medicine, has demonstrated significant potential with its expansive portfolio of advanced wound care and sports medicine products. The company operates in an underpenetrated market, highlighting opportunities for growth, especially with additional total addressable markets beyond wound care. As the company progresses through FY25, normalized operating dynamics are anticipated to lead to improved financial performance in the latter half of the fiscal year.

Bears say

Organogenesis Holdings Inc is facing significant downside risks concerning its PuraPly product growth, with potential impacts stemming from Medicare Part B pricing for amniotic products and regulatory hurdles that competitors may navigate more efficiently. The company's financial outlook has been further exacerbated by delays associated with the ReNu program, which incurred approximately $30 million in expenditures during FY24 and has postponed potential market clearance by several months. Additionally, challenges related to the uptake of new products and adverse clinical data outcomes contribute to a negative sentiment surrounding the company's capabilities to capture market share effectively.

Organogenesis Holdings (ORGO) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Organogenesis Holdings (ORGO) Forecast

Analysts have given Organogenesis Holdings (ORGO) a Buy based on their latest research and market trends.

According to 3 analysts, Organogenesis Holdings (ORGO) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Organogenesis Holdings (ORGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.